Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TBX-3400 |
Synonyms | |
Therapy Description |
TBX-3400 comprises autologous peripheral blood mononuclear cells that are treated with TBX-4000, a recombinant fusion protein consisting of the HIV TAT protein transduction domain fused to MYC, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TBX-3400 | TBX3400|TBX 3400 | TBX-3400 comprises autologous peripheral blood mononuclear cells that are treated with TBX-4000, a recombinant fusion protein consisting of the HIV TAT protein transduction domain fused to MYC, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04640246 | Phase Ib/II | TBX-3400 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | Unknown status | USA | ISR | 0 |
NCT03385486 | Phase I | TBX-3400 | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors | Unknown status | USA | 0 |